Excimer Laser, Serum Markers & Psoriasis
| Status: | Recruiting |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | September 2013 |
| End Date: | September 2016 |
| Contact: | Amanda Suggs, MD |
| Email: | amanda.suggs@uhhospitals.org |
| Phone: | 2168447546 |
Effects of UVB Excimer Laser on Serum Inflammatory Markers in Patients With Psoriasis
The overall aims for this study are to determine whether UVB excimer laser treatment of
psoriasis affects serum inflammatory markers, and to assess hyperpigmentation and erythema
with excimer laser treatment.
The investigators hypothesize that treatment of psoriasis with UVB delivered via 308 nm
excimer laser will decrease the levels of serum inflammatory markers. The investigators
hypothesize that treatment will decrease plaque erythema and will result in minimal
hyperpigmentation.
psoriasis affects serum inflammatory markers, and to assess hyperpigmentation and erythema
with excimer laser treatment.
The investigators hypothesize that treatment of psoriasis with UVB delivered via 308 nm
excimer laser will decrease the levels of serum inflammatory markers. The investigators
hypothesize that treatment will decrease plaque erythema and will result in minimal
hyperpigmentation.
Subjects will undergo Excimer treatment twice a week until they reach a PASI 75 improvement,
or until they reach the maximum of 20 total treatments. A blood draw to assess serum
inflammatory markers will be performed at the screening visit and final visit. Chromameter
assessment, photographs, PASI and PGA (Physician Global Assessment) will be performed
throughout the study to monitor psoriasis improvement, hyperpigmentation and erythema.
or until they reach the maximum of 20 total treatments. A blood draw to assess serum
inflammatory markers will be performed at the screening visit and final visit. Chromameter
assessment, photographs, PASI and PGA (Physician Global Assessment) will be performed
throughout the study to monitor psoriasis improvement, hyperpigmentation and erythema.
Inclusion Criteria:
- Age 18 years and older
- Male or female with diagnosis of psoriasis
- Psoriasis involvement of 5-15% BSA
- Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic
agents, etc) for at least 4 weeks
- Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2
weeks
- Fitzpatrick Skin Types I-VI
Exclusion Criteria:
- Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus,
porphyria, severe polymorphous light eruption, solar urticaria)
- Any suspicion that the psoriasis is of the photosensitive variant.
- Any medical condition that could be aggravated or may cause extreme discomfort during
the study period.
We found this trial at
1
site
Click here to add this to my saved trials
